Key Highlights

  • Revenue increased 19% year over year to $2.89 billion, supported by higher procedure volumes, stronger leasing activity, and installed base expansion.
  • Worldwide procedures grew approximately 16%, with da Vinci procedures increasing 15% and Ion procedures rising 36%.
  • GAAP diluted EPS improved to $2.29, while non-GAAP diluted EPS reached $2.80.
  • The company placed 468 da Vinci systems, including 246 da Vinci 5 systems, while expanding its installed base to 11,710 systems globally.

Intuitive Surgical Q2 2026 Earnings: Strong Execution Reinforces Leadership in Robotic Surgery

Intuitive Surgical delivered another impressive quarterly performance as continued adoption of its robotic-assisted surgical platforms fueled double-digit growth across revenue, procedures, profitability, and system placements. The company's expanding installed base, growing recurring revenue stream, and disciplined execution highlighted the resilience of its business model despite ongoing tariff-related cost pressures.

The results reaffirm that demand for minimally invasive robotic surgery remains strong across hospitals and healthcare systems worldwide, with the da Vinci ecosystem continuing to serve as the company's primary long-term growth engine.

Recurring Revenue Continues to Strengthen

Instrument and accessory revenue remained the largest contributor to quarterly sales as higher surgical volumes generated greater demand for recurring consumables. Service revenue also continued to expand alongside the growing installed base, reinforcing the stability and predictability of Intuitive's revenue model.

System revenue benefited from increased placements, stronger average selling prices, and continued adoption of leasing arrangements, allowing hospitals to expand robotic surgery programs while reducing upfront capital requirements.

Profitability and Cash Generation Remain Strong

Operating income and net income both improved significantly as revenue growth outpaced operating expense increases. The company also maintained healthy margins despite absorbing higher tariff costs, supported by operating leverage and a favorable product mix.

Intuitive ended the quarter with $8.63 billion in cash, cash equivalents, and investments while continuing shareholder returns through share repurchases during the quarter, demonstrating the company's strong balance sheet and financial flexibility.

2026 Outlook Signals Continued Confidence

Management reaffirmed confidence in the long-term demand for robotic-assisted surgery by forecasting worldwide da Vinci procedure growth of approximately 13.5% to 15.5% for 2026, with expectations centered near the midpoint of that range.

The company also maintained guidance for healthy non-GAAP gross margins and disciplined operating expense growth, although management cautioned that additional tariffs could create incremental cost pressures if current trade conditions worsen.

Investor Reaction and Market Outlook

The quarterly results reinforced Intuitive Surgical's position as the clear leader in robotic-assisted surgery. Strong procedure growth, accelerating da Vinci 5 adoption, expanding recurring revenue, and sustained profitability are likely to strengthen investor confidence in the company's long-term growth trajectory.

While tariffs remain an external risk that investors will continue to monitor, the combination of robust demand, expanding installed base, consistent cash generation, and continued innovation positions Intuitive Surgical to remain one of the highest-quality growth companies in the medical technology sector.

1. How did Intuitive Surgical perform in Q2 2026?

Intuitive Surgical reported a strong second quarter, delivering double-digit growth in revenue, procedures, system placements, and earnings. The company's expanding installed base and higher recurring revenue from instruments, accessories, and services were the primary drivers of performance.

2. What drove Intuitive Surgical's revenue growth?

Revenue growth was supported by higher worldwide procedure volumes, increased placements of da Vinci surgical systems, stronger leasing revenue, and continued expansion of both the da Vinci and Ion installed bases.

3. What is the outlook for Intuitive Surgical in 2026?

The company expects worldwide da Vinci procedure growth to remain in the mid-teens during 2026 while maintaining healthy profitability. Management also expects operating expenses to remain disciplined, although tariffs could continue to affect margins if trade conditions worsen.